A Retrospective, Single-Institutional Study Assessing the Safety of TAS-102 with Bevacizumab in Patients with Refractory Metastatic Colorectal Cancer (mCRC) in Real-World Clinical Practice

Trial Profile

A Retrospective, Single-Institutional Study Assessing the Safety of TAS-102 with Bevacizumab in Patients with Refractory Metastatic Colorectal Cancer (mCRC) in Real-World Clinical Practice

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Feb 2018 New trial record
    • 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top